GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment

Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Today
—
Total
BSE
Exchange
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Corona Remedies Ltd
Corona Remedies Board Approves FY26 Results, Recommends ₹10 Final Dividend
RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 11 May 2026, 05:12 PM IST  ·  BSE ID: eb0fd48c-9e5a-4829-8dd9-ec0248db0744
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board approved its yearly financial results and proposed a ₹10 dividend per share, setting June 19, 2026, as the record date.
🤖 AI Summary
  • Board approved audited Standalone and Consolidated Financial Results for FY ended March 31, 2026.
  • Final dividend of ₹10 (100%) per equity share of face value ₹10 recommended for FY26.
  • Record Date for final dividend is fixed as Friday, June 19, 2026.
  • Auditor's reports on Standalone and Consolidated Financial Results are unmodified.
  • M/s. Walker Chandiok & Co LLP recommended as Statutory Auditor for five years (FY27-FY31).
🔢 Key Numbers — exact figures from BSE filing, not rounded
Final Dividend per Equity Share
₹10
Face Value per Equity Share
₹10
Dividend Percentage
100%
🏢 How This Affects the Company
💰
Financial Impact
The recommended final dividend of ₹10 per equity share will result in a cash outflow for the company upon approval and payment to shareholders.
⚙️
Operational Impact
The appointment of new statutory, secretarial, internal, and cost auditors will change external oversight and internal compliance mechanisms. The re-appointment of the Non-Executive Director maintains continuity in board leadership.
⚠️
Risk Impact
The unmodified audit reports indicate no significant accounting discrepancies, reducing financial reporting risk. The appointment of new auditors and re-appointment of a director are standard corporate governance practices.
👥 What This Means For Shareholders
✅
Action Required
Shareholders holding shares on the Record Date of June 19, 2026, will be entitled to receive the final dividend, if approved at the AGM.
👤
Who Is Affected
Shareholders on record as of June 19, 2026, will be affected by the dividend payment. The dividend of ₹10 per equity share is for shares with a face value of ₹10 each.
🔍
Management Signal
Management intends to return capital to shareholders through a dividend and is upholding corporate governance standards with auditor appointments and director re-appointment.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Annual General Meeting (AGM) — shareholder approval of dividend and auditor appointments.
Dividend payment — check for payment on or before August 07, 2026.
Full FY26 Financial Results — review detailed figures once released.
LOW RISK The filing reports standard board approvals and dividend recommendation with unmodified audit reports.
💡 Investor Takeaway
The Board approved the audited Standalone and Consolidated Financial Results for the year ended March 31, 2026, with unmodified audit reports. A final dividend of ₹10 (100%) per equity share of face value ₹10 has been recommended for FY26, with a Record Date of June 19, 2026.
⚖️ Strengths & Concerns

✅ Positives

  • Auditor's reports on both Standalone and Consolidated Financial Results are unmodified, indicating no material misstatements.
  • Recommendation of a final dividend of ₹10 (100%) per equity share for FY 2025-26, pending shareholder approval.
📅 Company Track Record
No previous filings containing financial results or dividend declarations were found for Corona Remedies Ltd. The company was incorporated on CIN L24231GJ2004PLC044656.

Based on publicly available historical data. For context only.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.